Global Rosuvastatin Market growing at a CAGR of 4.0% from 2023 to 2031
Category : Healthcare | Published Date : Dec 2023 | Type : Press Release
Key Market Overview
Consegic Business Intelligence analyzes that the rosuvastatin market is predicted to grow at a compound annual growth rate of 4.0% from 2023 to 2031 and is expected to reach USD 655.99 million in 2031 and 480.58 million in 2023 which was valued at USD 463.85 million in 2022.
The report highlights the growing incidences of cardiovascular diseases across the globe, which is augmenting the global market growth. Consegic Business Intelligence study also provides insights into the market's competitive landscape, market segmentation, regional outlook, and emerging technologies in the rosuvastatin market.
Global Rosuvastatin Market By Overview
The rosuvastatin market is bifurcated into the application, dosage form and distribution channel. Based on the application, the market is segmented into obesity, dyslipidaemia, atherosclerosis, heart stroke, and others. In 2022, the dyslipidaemia and atherosclerosis, segment dominate the overall rosuvastatin market. Based on the dosage form, the market is segmented into capsules and tablets. In 2022, the capsules segment dominates the overall rosuvastatin market. Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and drug stores, online pharmacies, and others. In 2022, retail pharmacies and drug stores dominate the overall rosuvastatin market.
Get Free SampleMarket Dynamics
Driver:
- Growing incidences of cardiovascular diseases across the globe.
- Rising awareness about health risks related to high cholesterol and obesity.
Restraints:
- New alternative product launches and competitor drugs to Rosuvastatin.
Market Segmentation:
| Report Attributes | Report Details |
| By Application | Obesity, Dyslipidemia, Atherosclerosis, Heart stroke, and Others |
| By Dosage Form | Capsules and Tablets |
| By Distribution Channel | Hospital Pharmacies, Retail Pharmacies and Drug Stores, Online Pharmacies, and Others. |
| By Region | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Competitive Landscape :
The market is dominated by certain major companies such as Glenmark Pharmaceuticals U.S. Inc., USA, AstraZeneca, Sun Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd., which have a strong market position in the current market circumstances. These companies are continuously leveraging new technologies to develop innovative solutions. Furthermore, the rosuvastatin market is expected to witness substantial growth in the coming years due to rising fitness and wellness trends among consumers in key regions such as North America, Asia Pacific, and others.
The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships.
- Glenmark Pharmaceuticals U.S. Inc., USA
- AstraZeneca
- AdvaCare Pharma
- Niksan Pharmaceutical
- Teva Pharmaceutical Industries
- MANUS AKTTEVA BIOPHARMA LLP
- Nextwell Pharmaceutical
- Schwitz Biotech
- XENON PHARMA PVT LTD
- Saheb Pharmaceuticals LLP
- MSN Laboratories
- Shanghai Pharma Holdings Co., Ltd
- Lunan Pharmaceutical Group
- JB Pharma.
- Grünenthal
